Gilead and Glympse Bio Announce Strategic Collaboration for Use of Biomarker Technology in NASH Clinical Development
28.10.2019 15:00:00 EET | Business Wire | Press release
Gilead Sciences Inc. (Nasdaq: GILD) and Glympse Bio, Inc., today announced that the companies have entered into a strategic collaboration in nonalcoholic steatohepatitis (NASH) clinical development. Glympse Bio’s proprietary synthetic biomarkers – bioengineered to identify stage and progression of disease as well as early detection of treatment response – will be used to determine clinical trial participants’ stage of disease at initial screening and to determine responses to study treatment in Gilead’s NASH clinical program.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191028005145/en/
“We are excited about the opportunity to partner with Glympse Bio to help inform our NASH development program,” said Mani Subramanian, MD, PhD Senior Vice President, Liver Diseases, Gilead Sciences. “By utilizing this innovative technology, we hope to better characterize this complex disease and improve our understanding of how our compounds impact disease progression.”
Glympse Bio’s proprietary technology, Glympse Inside™, combines synthetic biomarkers with machine learning approaches to identify the stage and monitor progression of important, complex diseases such as cancer, fibrosis, inflammation, and infections, in real time.
“We are very excited about partnering with Gilead, a leader in drug development, to help drive earlier and more favorable outcomes for patients,” said Caroline J Loew, President and CEO, Glympse Bio. “Gilead’s commitment to developing innovative medicines in areas of high unmet medical need aligns with our mission of transforming disease detection and measuring treatment response, all with the goal of helping improve the lives of patients.”
Financial terms of the agreement were not disclosed.
About Glympse Bio
Glympse Bio is pioneering the development of disruptive, non-invasive technology to directly query disease activity inside the body. The Company’s proprietary synthetic biomarkers – biological sensors developed using breakthroughs in science, engineering, medicine and artificial intelligence – are potentially tunable to a multitude of diseases and offer earlier measures of response to disease and treatment. By integrating real-time biological activity with sophisticated machine learning and artificial intelligence, Glympse Inside™ is a pan-disease product engine that aims to transform disease monitoring and treatment response. The company is based at the Lab Central incubator in Cambridge, MA. For more information, please visit http://www.glympsebio.com.
About Gilead Sciences
Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company’s mission is to advance the care of patients suffering from life-threatening diseases. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.
Gilead Forward-Looking Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the risk that the parties may not realize the potential benefits of this collaboration. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in Gilead’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2019, as filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.
For more information on Gilead Sciences, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191028005145/en/
Contact information
Sung Lee, Investors
(650) 524-7792
Beth Kurth
(617) 584-9650
bkurth@conwaycommsir.com
Arran Attridge, Media
(650) 425-8975
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lenovo Announces Tech World @ CES 2027: Defining the Next Era of Hybrid AI7.10.2026 16:01:00 EEST | Press release
Lenovo, the global technology powerhouse, today announced that its annual global innovation event will return to CES® 2027 in Las Vegas. Hosted at Sphere and part of the CES Keynote lineup, Tech World will bring together a visionary lineup of speakers and breakthrough innovations with a first-of-its-kind immersive technology and music experience. As well as unveiling the latest in Lenovo’s innovations, Tech World will unite global technology leaders and leading voices on stage to discuss the future of AI. Together, they will explore how hybrid AI can empower people and unlock new possibilities for business and society. As demand grows for responsible AI leadership, the event will provide a defining moment at the start of 2027 to consider AI’s role in unlocking human potential, sustaining the planet, and driving global progress. “AI is entering a new phase, where every individual and every enterprise should be empowered to transform data into real value,” said Yuanqing Yang, Lenovo Chai
Rivercell Launches With $25 Million to Build Data Platforms and AI Models That Predict How Human Cells Respond to Treatment7.10.2026 16:00:00 EEST | Press release
Rivercell, a Paris-based biotechnology and AI company building its own data infrastructure on how human cells respond to any treatment and training a world model of the cell that can predict those responses, today announced a $25 million seed round led by HV. HCVC, Alven and Bpifrance Digital Venture also participated in the round, which will fund the scale-up of Rivercell’s proprietary data generation platform, the expansion of its wet lab in Paris (a lab working with chemicals and biological samples), and the launch of its AI Virtual Cell program. Being indication-agnostic, Rivercell's world model can drive groundbreaking discovery across any cell behavior that leads to disease because it learns the underlying rules of how human cells respond to drugs and genetic changes, not the features of a single disease. Rivercell was started in summer 2025 by CEO Yann Fleureau, the engineer-turned-entrepreneur behind AI company Cardiologs, joined in 2026 by CSO Eric Durand, an AI scientist and
NTT DATA Opens AI Factory Munich Where Clients Can Validate their AI in a Live Environment7.10.2026 16:00:00 EEST | Press release
NTT DATA, a global leader in AI, digital business and technology services, today opened the NTT DATA AI Factory Munich, a real-world environment where clients can test how their AI applications will perform at scale before they invest in broad deployments. Unlike a traditional AI demonstration or innovation lab, the AI Factory Munich operates within a live data center environment (NTT Global Data Centers' Munich 2 Data Center), allowing clients to evaluate AI workloads against the infrastructure, security, data, governance and operational requirements they will face in production. AI deployments typically stall between pilots that prove an idea and enterprise-scale production that delivers value. To bridge this gap, the AI Factory Munich leverages NTT DATA’s capabilities from consulting, infrastructure and AI platforms to managed services, data centers and its global partner ecosystem. Among active partners, NVIDIA provides an accelerated computing platform, including NVIDIA Blackwell
Print Infrastructure Is the Biggest Zero Trust Gap CIOs Haven’t Closed, Survey Finds7.10.2026 15:30:00 EEST | Press release
Vasion today released new research revealing a security gap hiding in plain sight across enterprise IT: CIOs and IT leaders know their print environments carry risk, but print remains largely outside their Zero Trust strategies even as failures continue to disrupt business operations. According to an independent survey of 500+ enterprise CIOs and senior IT leaders commissioned by Vasion through Censuswide, 54% of respondents describe their print environment as “actively managed, with known and accepted risks.” At the same time, 61% report that print or document workflow failures disrupt their business at least once a week. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261007677295/en/ Print Infrastructure Is the Biggest Zero Trust Gap CIOs Haven’t Closed, Survey Finds The finding points to a broader issue: print may not be viewed as broken, but it remains an accepted area of exposure and operational friction. The gap become
Oscilloquartz expands OSAinside ™ Series OSA 5400 TimeCard ™ with advanced server-integrated timing capabilities7.10.2026 15:00:00 EEST | Press release
Oscilloquartz today announced significant new capabilities for its OSAinside™ Series OSA 5400 TimeCard™, expanding the flexibility and performance of server-integrated timing for defense, data center, telecom and finance applications. With support for multiple deployment architectures and timing sources, the enhanced OSA 5400 TimeCard™ enables organizations to integrate highly accurate synchronization directly into commercial off-the-shelf (COTS) and purpose-built servers, reducing reliance on dedicated external timing appliances. Available as the OSA 5400 TimeCard™ and the OSA 5400 TAP TimeCard™, the platform supports PCIe Precision Time Measurement (PTM), multi-band L1/L5 GNSS with NavIC and Galileo OSNMA, advanced jamming and spoofing detection and multiple oscillator options for precise server-level synchronization. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261007831264/en/ Oscilloquartz’s enhanced OSA 5400 TimeCard
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom